Skip to content
Screener

Shattuck Labs, Inc. STTK Business Segments — Research and development equity compensation

Similar metrics at other companies

Biogen logo
BIIBReportable Segment — Research and development:
$167.1M-0.7%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Stock Based Compensation
$19.33M+63.5%
Viridian Therapeutics, Inc. logo
VRDNReportable Segment — Segment research and development expense
$64.19M-21.1%
Zoom Video Communications, Inc. logo
ZMReportable Segment — Adjusted research and development
$153.11M+20.5%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other research and development
$2.91M-7.8%
UiPath logo
PATHReportable Segment — Adjusted research and development
$67.72M+12.5%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept sttk:ResearchAndDevelopmentEquityCompensation.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —
SL-84611,679
Other research and development22,4792,878
Research and development non-equity compensation2,3602,331
Research and development equity compensation1,075867
Total research and development11,7008,680
General and administrative expenses:
General and administrative non-equity compensation1,3971,365
General and administrative equity compensation1,6581,023

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s business segments — research and development equity compensation?
Shattuck Labs, Inc. (STTK) reported business segments — research and development equity compensation of $1.08M in Q2 2026.
How has Shattuck Labs, Inc.'s business segments — research and development equity compensation changed year-over-year?
Shattuck Labs, Inc.'s business segments — research and development equity compensation increased by 24.0% year-over-year, from $867K to $1.08M.
What is the long-term trend for Shattuck Labs, Inc.'s business segments — research and development equity compensation?
Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s business segments — research and development equity compensation has grown at a -7.7% compound annual growth rate (CAGR), from $3.46M to $2.95M.
What does business segments — research and development equity compensation mean?
Reflects the non-cash expense associated with stock-based compensation granted to research and development staff. This metric provides insight into the company's strategy for talent retention and alignment of employee incentives with long-term shareholder value in the R&D function.

Ask your AI about Shattuck Labs, Inc.'s business segments — research and development equity compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude